What to Expect from Johnson & Johnson’s Fourth Quarter Results
- Johnson & Johnson expected to post 4Q net income growth
- Lower revenue compared to last year
- Adjusted earnings expected to be $2.28 per share
- Outlook for 2023 and beyond to be discussed
- Details on recent acquisition of Ambrx Biopharma
- Succession rate at Johnson & Johnson may be a concern
Johnson & Johnson is set to report its fourth-quarter results, with expectations of net income growth and lower revenue compared to the previous year. The healthcare company is projected to post net income of $4.37 billion, up from $3.52 billion a year earlier. However, revenue is expected to decline to $21.02 billion from $23.71 billion. Adjusted earnings are estimated to be $2.28 per share. Investors will be keen to hear about Johnson & Johnson’s outlook for 2023 and beyond, as the company raised its sales and earnings per-share outlook for that period. Additionally, details about the recent acquisition of Ambrx Biopharma, a cancer-treatment developer, are anticipated. Concerns about the succession rate at Johnson & Johnson may also be on investors’ minds, as potential candidates for the top job are discussed.
Public Companies: Johnson & Johnson (JNJ)
Private Companies:
Key People: Jennifer Taubert (Pharmaceuticals Business Head), Joseph Wolk (Chief Financial Officer), Ashley McEvoy (Former Medical-Device Head), Joaquin Duato (Chief Executive Officer)
Factuality Level: 8
Justification: The article provides factual information about Johnson & Johnson’s expected net income, revenue, and adjusted earnings for the fourth quarter. It also mentions the company’s outlook for 2023 and beyond, as well as its recent acquisition of Ambrx Biopharma. The information about the succession rate at Johnson & Johnson is based on a report from The Wall Street Journal. Overall, the article presents relevant and accurate information without any obvious bias or misleading content.
Noise Level: 7
Justification: The article provides relevant information about Johnson & Johnson’s upcoming fourth-quarter results, including net income, revenue, and adjusted earnings. It also mentions the company’s outlook for 2023 and beyond, an acquisition, and the succession rate at Johnson & Johnson. However, the article lacks in-depth analysis, scientific rigor, and actionable insights. It mainly focuses on reporting facts without providing much context or critical analysis.
Financial Relevance: Yes
Financial Markets Impacted: The financial markets that may be impacted by Johnson & Johnson’s fourth-quarter results include the healthcare sector and pharmaceutical industry. Investors and analysts will be closely watching the company’s net income, revenue, and adjusted earnings to assess its financial performance and make investment decisions.
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The news article does not mention any extreme events or events that would have a significant impact on financial markets or companies. It primarily focuses on Johnson & Johnson’s upcoming fourth-quarter results, outlook for 2023, recent acquisition, and potential succession plans.
www.marketwatch.com 
